Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Bristol
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1179)
•••
Post by Duster340on Jun 04, 2022 11:41am
220 Views
Post# 34731661

RE:RE:RE:RE:RE: Bristol

RE:RE:RE:RE:RE: BristolMugsy Wrote: OK - kindly talk to an amazing Phase 2A and 2B and tell me how you see it relating to acute pain.

Tell me how you thing ATE is going to solve chronic

Wait - on second thought ... don’t.

Already placed my bets and I’m thinking way beyond your fears.

past 352 and cancer pain ... past metastasis ... past IBD and all the wonderful angles there.

Im on 340 and future drug delivery.

so ... am I projecting?
you’re darn right I’m projecting.

That’s what I do - I look to the future.

That’s how I place my bets in a very difficult space like this.

Maybe I should apologize ... but I won’t !

Hahaha!  Go Antibe !!!!! 

Duster340 Writes: mugsy is way ahead of the stock market which is forward looking, but has not yet recognized the potential of ate, but that has a lot to do with market sentiment if there was no inflation, no war in ukraine, no interest rate hikes. i believe ate would be well over $1 today. unfortunatley that is not the case so in this environment we need positive news to be rewarded.  maybe mugsy is like gretzky, it's not going to where the puck is, it is going to where the puck is going to be  hahaha.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities